Veru announces meta-analysis of body composition data from older patients with obesity which supports potential for enobosarm to optimize weight loss at obesityweek

Miami, fl, nov. 05, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at obesityweek, which took place november 5, 2024, in san antonio, texas.
VERU Ratings Summary
VERU Quant Ranking